UBS analyst AJ Rice raised the firm’s price target on BrightSpring Health (BTSG) to $53 from $48 and keeps a Buy rating on the shares. Growth momentum should continue into 2026 while BrightSpring invests for the future, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $50 from $40 at Deutsche Bank
- BrightSpring Health price target raised to $50 from $43 at Wells Fargo
- BrightSpring Health price target raised to $49 from $39 at Leerink
- BrightSpring Health Services Projects Strong 2026 Growth
- BrightSpring Health sees FY26 revenue $14.45B-$15B, consensus $14.62B